News / US / cnbc
HHS Reportedly Planning New FDA Leadership Roles for AI and Drug Oversight
Health Technology · Biotechnology · cnbc · 2026-08-25
QURE, REPL
The Department of Health and Human Services is considering adding two deputy commissioner positions to the FDA to bolster oversight of technology and pharmaceuticals.
What Happened
Proposed Leadership Expansion: The Department of Health and Human Services is reportedly planning to establish two new deputy commissioner roles within the Food and Drug Administration. These positions are intended to focus specifically on the rapidly evolving sectors of pharmaceutical regulation and the integration of artificial intelligence in healthcare.
Strategic Oversight and AI: One of the proposed roles would oversee the agency's internal adoption of AI tools while managing the regulatory framework for AI-enabled medical devices. Industry veteran Jared Seehafer has emerged as a primary candidate for this technology-focused leadership position, reflecting the administration's desire for specialized expertise.
Regulatory Context and Challenges: This potential restructuring follows a period of significant scrutiny regarding the FDA's handling of foodborne illness outbreaks and controversial drug approval decisions. The agency has recently faced criticism over its clinical trial requirements and fluctuating stances on accelerated approval pathways for various biotech treatments.
Administrative Influence: Sources suggest that these appointments are part of a broader effort by the current administration to exert greater control over the agency's operations. The new deputies would report directly to the incoming FDA commissioner, Heidi Overton, as the agency navigates complex pressures regarding its budget, staffing, and public trust.